Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ.
Knight DA, et al. Among authors: ribas a.
J Clin Invest. 2013 Mar;123(3):1371-81. doi: 10.1172/JCI66236. Epub 2013 Feb 1.
J Clin Invest. 2013.
PMID: 23454771
Free PMC article.